T0070907 is a potent and selective PPARγ inhibitor with IC50 of 1 nM, with a >800-fold selectivity over PPARα and PPARδ.
|Source||Environ Health Perspect (2018). Figure 3. T0070907|
|Cell Lines||human and mouse MSCs|
|Results||In hMSCs, T0070907 (100nM) significantly blocked the ability of DBT to induce the accumulation of lipids|
|Cell lines||MCF-7 cells|
|Preparation method||MTS assay|
|Concentrations||20 μM and higher concentrations|
|Incubation time||48 h|
|Animal models||Preconditioning is performed by administering a low dose (1 mg/kg) of Escherichia coli LPS (serotype 0.127:B8) intraperitoneally 24 hr before the induction of severe endotoxemia|
|Formulation||10% v/v dimethylsulfoxide [DMSO], 20–25% v/v DMSO, or saline|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 10 mg/mL|
|Related PPAR Products|
Rosiglitazone HCl is a blood glucose-lowering drugs, stimulating insulin secretion by binding to the PPAR receptors in fat cells.
All-trans retinoic acid (ATRA; Vitamin A acid) has been widely investigated for treatments of many cancers including prostate cancer.
Pioglitazone HCl is a selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, used to treat diabetes.
Fenofibric acid is a fibrate that acts as a lipid-lowering agent, decreasing low-density lipoprotein cholesterol and triglycerides.
Clofibrate (Atromid-S), a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.